Biomarin Pharmaceutical Inc. (BMRN)
Is the Options Market Predicting a Spike in BioMarin Pharmaceutical Stock?
Investors need to pay close attention to BioMarin Pharmaceutical stock based on the movements in the options market lately.
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
BioMarin Offers to Buy Inozyme for $270M to Boost Enzyme Therapy Biz
BMRN's acquisition of INZY is set to add a late-stage enzyme replacement therapy for a rare genetic condition. The deal is likely to be closed by September.
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why BioMarin Pharmaceutical (BMRN) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
BioMarin's First-Quarter Earnings & Sales Beat Estimates
BMRN reports encouraging first-quarter results. The company reiterates its financial guidance for 2025.
BioMarin Pharmaceutical (BMRN) Beats Q1 Earnings and Revenue Estimates
BioMarin Pharmaceutical (BMRN) came out with quarterly earnings of $1.13 per share, beating the Zacks Consensus Estimate of $0.94 per share. This compares to earnings of $0.71 per share a year ago.
Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why BioMarin Pharmaceutical (BMRN) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
BioMarin Pharmaceutical (BMRN) Earnings Expected to Grow: What to Know Ahead of Q1 Release
BioMarin (BMRN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
6 Stocks With Clear Price Dislocations That I Purchased During Wall Street's Historic Volatility
The old idiom "blink, and you'll miss it" might be the best descriptor of the historic volatility we've witnessed on Wall Street over the trailing week, as of this writing on April 9.
